BenevolentAI - Using AI to Disrupt Traditional Drug Discovery Process

Case Code: BSTR569
Case Length: 10 Pages
Period: 2013-2018
Pub Date: 2019
Teaching Note: Available

Price: Rs.300
Organization: BenevolentAI
Industry: Pharmaceutical
Countries: United Kingdom
Themes: Disruptive Innovation, Incremental Innovation, Strategic Innovation, Breakthrough Innovation, Traditional Drug Discovery Process

Abstract Case Intro 1 Case Intro 2 Excerpts

Introduction

On April 19, 2018, BenevolentAI (BAI), the largest Artificial Intelligence (AI) company in the private sector in Europe and among the top five privately owned AI companies in the world, raised US$115 million in its latest round of funding from investors. With this massive funding, BAI increased its market valuation to US$2 billion and planned to scale up its drug development and its AI platform, the 'Bioscience Machine Brain' (BMB). In June 2018, BAI was awarded the 'Technology Pioneer Status' by the World Economic Forum. Earlier, in 2017, BAI had received the 'Pharma Company of the year – SME' for the year 2017 at the annual CPhI Pharma Awards....

Buy this case study (Please select any one of the payment options)

Price: Rs.300

PayPal (7 USD)

Custom Search